Registry | Total trialsn = 160 | Total trials (2017–2018) n = 91 | Datasets accessed Total trials (2017–2018) n = 91 | |||
---|---|---|---|---|---|---|
Death n = 69 | Hospital visits n = 50 | Cancer registration n = 29 | Other n = 26 | |||
NHS Digital | 108 (68%) | 59 (65%) | 58 (84%) | 34 (68%) | 22 (76%) | 4 (15%) |
ISD-Scotland | 35 (22%) | 25 (27%) | 16 (23%) | 13 (26%) | 7 (24%) | 2 (8%) |
PHE | 15 (9%) | 11 (12%) | 3 (4%) | 6 (12%) | 10 (34%) | 1 (4%) |
SAIL | 9 (6%) | 6 (7%) | 2 (3%) | 5 (10%) | 2 (7%) | 1 (4%) |
ICNARC | 7 (4%) | 4 (4%) | 1 (1%) | 0 (0%) | 0 (0%) | 4 (15%) |
NWIS | 7 (4%) | 6 (7%) | 1 (1%) | 6 (12%) | 1 (3%) | 0 (0%) |
PICANet | 6 (4%) | 2 (2%) | 0 (0%) | 0 (0%) | 0 (0%) | 2 (8%) |
CPRD | 4 (3%) | 1 (1%) | 0 (0%) | 1 (2%) | 0 (0%) | 1 (4%) |
NHSBT | 3 (2%) | 3 (3%) | 0 (0%) | 0 (0%) | 0 (0%) | 2 (8%) |
TARN | 3 (2%) | 2 (2%) | 1 (1%) | 1 (2%) | 0 (0%) | 2 (8%) |
NELA | 2 (1%) | 2 (2%) | 0 (0%) | 0 (0%) | 0 (0%) | 2 (8%) |
NNRD | 2 (1%) | 2 (2%) | 1 (1%) | 1 (2%) | 0 (0%) | 2 (8%) |
PHW | 2 (1%) | 1 (1%) | 0 (0%) | 0 (0%) | 0 (0%) | 1 (4%) |
UKRR | 2 (1%) | 2 (2%) | 0 (0%) | 1 (2%) | 1 (3%) | 0 (0%) |
ResearchOne | 2 (1%) | 2 (2%) | 0 (0%) | 0 (0%) | 0 (0%) | 2 (8%) |
DOH | 1 (1%) | 0 (0%) | 0 (0%) | 0 (0%) | 0 (0%) | 0 (0%) |
FFFAP | 1 (1%) | 1 (1%) | 0 (0%) | 0 (0%) | 0 (0%) | 1 (4%) |
HBS | 1 (1%) | 1 (1%) | 0 (0%) | 0 (0%) | 0 (0%) | 1 (4%) |
NICOR | 1 (1%) | 1 (1%) | 1 (1%) | 0 (0%) | 0 (0%) | 0 (0%) |
NICR | 1 (1%) | 1 (1%) | 0 (0%) | 0 (0%) | 1 (3%) | 0 (0%) |
OHCAO | 1 (1%) | 1 (1%) | 0 (0%) | 0 (0%) | 0 (0%) | 1 (4%) |
UKCFR | 1 (1%) | 1 (1%) | 0 (0%) | 0 (0%) | 0 (0%) | 1 (4%) |